Inflammatory interstitial lung diseases
Conditions
Interventions
Pirfenidone:Pirfenidone with standard treatment
Nintedanib:Nintedanib with standard treatment
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age>=18 years old; 2.Inflammatory interstitial lung disease diagnosed within recent 4 weeks, presenting with radiological and/or pathological pattern of organizing pneumonia (OP), cellular nonspecific interstitial pneumonia (cNSIP), or OP+cNSIP pattern; 3.Require corticosteroid and/or immunosuppressant treatment;
Exclusion criteria
Exclusion criteria: 1.Patients or their family members are unable to provide informed consent; 2.Presence of other severe comorbidities that the investigator believes may affect patient safety or compliance; 3.Pregnant or breastfeeding women, as well as patients who cannot effectively practice contraception during the study period and for 3 months after completion; 4.Malignancies requiring treatment; 5.Allergy to pirfenidone or nintedanib; 6.Need for endotracheal intubation with mechanical ventilation or ECMO support;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forced Vital Capacity; | — |
Countries
China
Contacts
Public Contacthui huang
Peking Union Medical College Hospital
Outcome results
None listed